PE20021138A1 - USE AND COMPOSITIONS OF ANTIPROGESTINES FOR THE TREATMENT OF DISEASES OF THE PROSTATE - Google Patents

USE AND COMPOSITIONS OF ANTIPROGESTINES FOR THE TREATMENT OF DISEASES OF THE PROSTATE

Info

Publication number
PE20021138A1
PE20021138A1 PE2002000438A PE2002000438A PE20021138A1 PE 20021138 A1 PE20021138 A1 PE 20021138A1 PE 2002000438 A PE2002000438 A PE 2002000438A PE 2002000438 A PE2002000438 A PE 2002000438A PE 20021138 A1 PE20021138 A1 PE 20021138A1
Authority
PE
Peru
Prior art keywords
prostate
diseases
treatment
antiprogestines
compositions
Prior art date
Application number
PE2002000438A
Other languages
Spanish (es)
Inventor
Ulrike Fuhrmann
Jens Hoffmann
Gerhard Siemeister
Martin Schneider
Rosemarie Lichtner
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of PE20021138A1 publication Critical patent/PE20021138A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE AL USO DE LA ANTIPROGESTINA 11ß-(4-ACETILFENIL)-17ß-HIDROXI-17O-(1,1,2,2,2-PENTAFLUOROETIL)-ESTRA-4,9-DIEN-3-ONA, UN DERIVADO O ANALOGO DE LA MISMA UTIL PARA EL TRATAMIENTO DE ENFERMEDADES DE LA PROSTATA COMO CANCER EN UNA CANTIDAD DE 50 mg A 100mg. LA ANTIPROGESTINA SE PUEDE COMBINAR CON UN DERIVADO U OTRO AGENTE TERAPEUTICO SELECCIONADO DE ANTIOANDROGENOS, ESTROGENOS, ANTIESTROGENOS, INHIBIDORES DE LA 5a-REDUCTASA, DROGAS CITOSTATICAS, ENTRE OTROSREFERS TO THE USE OF THE ANTIPROGESTIN 11ß- (4-ACETYLPHENYL) -17ß-HYDROXY-17O- (1,1,2,2,2-PENTAFLUOROETHYL) -ESTRA-4,9-DIEN-3-ONA, A DERIVATIVE OR ANALOGUE OF THE SAME USEFUL FOR THE TREATMENT OF DISEASES OF THE PROSTATE SUCH AS CANCER IN AN AMOUNT OF 50mg TO 100mg. THE ANTIPROGESTIN CAN BE COMBINED WITH A DERIVATIVE OR ANOTHER SELECTED THERAPEUTIC AGENT OF ANTIOANDROGENS, ESTROGINS, ANTIESTROGENS, 5a-REDUCTASE INHIBITORS, CYTOSTATIC DRUGS, AMONG OTHERS

PE2002000438A 2001-05-25 2002-05-24 USE AND COMPOSITIONS OF ANTIPROGESTINES FOR THE TREATMENT OF DISEASES OF THE PROSTATE PE20021138A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01250185 2001-05-25

Publications (1)

Publication Number Publication Date
PE20021138A1 true PE20021138A1 (en) 2003-01-11

Family

ID=8181589

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000438A PE20021138A1 (en) 2001-05-25 2002-05-24 USE AND COMPOSITIONS OF ANTIPROGESTINES FOR THE TREATMENT OF DISEASES OF THE PROSTATE

Country Status (6)

Country Link
EP (1) EP1392399A1 (en)
JP (2) JP2004531561A (en)
AR (1) AR034046A1 (en)
PE (1) PE20021138A1 (en)
UY (1) UY27301A1 (en)
WO (1) WO2002094379A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3733478A1 (en) * 1987-10-01 1989-04-13 Schering Ag ANTIGESTAGEN AND ANTIOOTROGENIC COMPOUNDS FOR THE INTRODUCTION OF BIRTH AND PREGNANCY, AND THE TREATMENT OF GYNAECOLOGICAL DISORDER AND HORMONE-RELATED TUMORS
DE4039561A1 (en) * 1990-12-07 1992-07-09 Schering Ag USE OF ANTIGESTAGENS FOR THE MANUFACTURE OF MEDICAMENTS
DE4318371A1 (en) * 1993-05-28 1994-12-01 Schering Ag Agent containing a compound with antiandrogenic and a compound with competitive, progesterone-antagonistic effect
DE19706061A1 (en) * 1997-02-07 1998-08-13 Schering Ag Anti-gestagen effective steroids with fluorinated 17alpha alkyl chain
WO2002032430A1 (en) * 2000-10-18 2002-04-25 Schering Aktiengesellschaft Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases
UA76729C2 (en) * 2000-10-18 2006-09-15 Шерінг Акцієнгезельшафт USE OF ANTIPROGESTIN 11<font face="Symbol">b</font>-(4-ACETYLPHENYL)-17<font face="Symbol">b</font>-HYDROXY-17<font face="Symbol">a</font>-(1,1,2,2,2-PENTAFLUOROETHYL)-ESTRA-4,9-DIEN-3-ONE FOR CANCER TREATMENT BY MEANS OF APOPTOSIS INDUCTION

Also Published As

Publication number Publication date
JP2010077157A (en) 2010-04-08
WO2002094379A1 (en) 2002-11-28
EP1392399A1 (en) 2004-03-03
UY27301A1 (en) 2003-02-28
AR034046A1 (en) 2004-01-21
JP2004531561A (en) 2004-10-14

Similar Documents

Publication Publication Date Title
HUP0303271A2 (en) Use of rapamycin for preparation of pharmaceutical composition suitable for cancer treatment
BRPI0415971A (en) method for treating, preventing or controlling macular degeneration, and pharmaceutical composition
UY28213A1 (en) NEW CYANOPIRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS.
MA26843A1 (en) NOVEL TOPICAL ESTRO-PROGESTIVE COMPOSITIONS WITH SYSTEMIC EFFECT
BRPI0416260A (en) method for treating, preventing or controlling an asbestos-related disease or disorder and pharmaceutical composition
UY26635A1 (en) SYNERGIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
NO20065368L (en) Therapeutic compositions containing at least one pyrrolobenzodiazepine derivative and fludarabine
BRPI0415007A (en) method for treating, preventing, modifying or administering pain and pharmaceutical composition
HUP0301405A2 (en) Compositions containing therapeutically active components having enhanced solubility
EA200500149A1 (en) Tissue Protective Cytokines for the Protection, Restoration and Stimulation of Reactive Cells, Tissues and Organs
BR0107869A (en) Electrogenated pharmaceutical compositions
BR0108930A (en) Method of delivering an active agent to a cell type of interest, pharmaceutical composition, caspase-activated prodrug, kit, method of treating mammals, using a caspase conjugate and using a pro-agent
CY1107906T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING OSTETROL PRODUCTS FOR USE IN CANCER TREATMENT
HN2001000244A (en) SPIROPIRIMIDIN INHIBITORS - 2, 4, 6 - TRIONA METALOPROTEINASAS.
ES2267706T3 (en) AGENTS AS NICOTINAMIDE OR CARDR FOR THE TREATMENT OF SKIN DISORDERS.
AR004089A1 (en) USE OF A SUBSTANCE P ANTAGONIST IN A TOPIC COMPOSITION, AS AN ANTIPERSPIRANT AGENT.
ATE324112T1 (en) TOPICAL TREATMENT FOR MASTALGIA
NO20073575L (en) Pharmaceutical compositions for the treatment of cellulite
GT200000194A (en) COMBINATION CHEMOTHERAPY.
BR0315931A (en) Method of treating, preventing or controlling macular degeneration and pharmaceutical composition
BR0315609A (en) Method of treating, preventing, modifying or controlling pain and pharmaceutical composition
ES2150404T3 (en) PHARMACEUTICAL COMPOSITIONS OF TIZOXANIDA AND NITOZOXANIDA.
PE20021138A1 (en) USE AND COMPOSITIONS OF ANTIPROGESTINES FOR THE TREATMENT OF DISEASES OF THE PROSTATE
BRPI0416870A (en) synergistically anticancer compositions
BRPI0418801A (en) methods of treating, controlling or preventing a specific cancer, and a disease associated with unwanted angiogenesis, reducing or preventing an adverse effect, pharmaceutical composition, and kit

Legal Events

Date Code Title Description
FA Abandonment or withdrawal